Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Receivables (2016 - 2025)

Historic Receivables for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $267.1 million.

  • Integra Lifesciences Holdings' Receivables rose 427.99% to $267.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.1 million, marking a year-over-year increase of 427.99%. This contributed to the annual value of $278.5 million for FY2024, which is 370.72% up from last year.
  • According to the latest figures from Q3 2025, Integra Lifesciences Holdings' Receivables is $267.1 million, which was up 427.99% from $288.0 million recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Receivables peaked at $288.0 million during Q2 2025, and registered a low of $230.0 million during Q1 2021.
  • For the 5-year period, Integra Lifesciences Holdings' Receivables averaged around $258.2 million, with its median value being $257.6 million (2025).
  • Data for Integra Lifesciences Holdings' Receivables shows a peak YoY increase of 2746.25% (in 2021) and a maximum YoY decrease of 925.05% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Receivables stood at $243.2 million in 2021, then grew by 12.47% to $273.6 million in 2022, then decreased by 1.84% to $268.6 million in 2023, then grew by 3.71% to $278.5 million in 2024, then decreased by 4.1% to $267.1 million in 2025.
  • Its last three reported values are $267.1 million in Q3 2025, $288.0 million for Q2 2025, and $257.6 million during Q1 2025.